Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the second round of recipients of its HIV cure grants program. This new commitment will provide $7.5 million to support five additional HIV cure research initiatives led by top academic institutions and focused on translational research and efficacy studies in preclinical models.
“Finding a cure for HIV is a formidable challenge to the scientific community. Together with our newest grant recipients, all of whom have a record of excellence in their research, we can take collective steps to help end this devastating epidemic,” said William Lee, Ph.D., Executive Vice President, Research, Gilead Sciences. “We are proud to support these leaders in HIV research and are confident in their ability to make meaningful and measurable contributions in this area of unmet medical need.”
The following organizations and corresponding projects will receive grants from Gilead to help fund their activities (Institution/Principal Investigator/Project Name):
- University of California, San Francisco, School of Medicine, Microbiology and Immunology, Chan Zuckerberg Biohub – Alexander Marson, M.D., Ph.D. – An Integrated CRISPR Platform to Discover Regulators of HIV Latency in Primary Human T Cells
- Institute of Human Genetics, French National Center for Scientific Research (CNRS) and University of Montpellier – Monsef Benkirane, Ph.D. – Paving the Way Towards Elimination of HIV Persistent CD4T Cell In Vivo
- University of Massachusetts Medical School – Abraham L. Brass, M.D., Ph.D. – A CRISPR/Cas9 Screen to Discover HIV-1 Latency Factors
- Frederick National Laboratory for Cancer Research, AIDS and Cancer Virus Program – Jeffrey D. Lifson, M.D. – TLR Ligand Augmented, Tissue Homing AIDS Virus-Specific Adoptive Cell Therapy to Target Viral Reservoirs
- Dana-Farber Cancer Institute – Joseph G. Sodroski, M.D. – Unlocking HIV-1 Env to Deplete Viral Reservoirs
The HIV cure grants program, initially announced in February 2016, underscores Gilead’s commitment to cure and ultimately eradicate HIV and AIDS through its research and development and philanthropic leadership. The first set of HIV cure grants, totaling more than $22 million, were awarded to 12 projects in January 2017.
For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. In further efforts to end the HIV epidemic, Gilead is conducting early-stage clinical research to identify novel agents and strategies that could play a role in eradicating HIV infection in the body.
Gilead’s corporate giving program aims to reduce health disparities, provide access, advance medical education and support local communities. In 2016, Funders Concerned About AIDS (FCAA) recognized Gilead as the leading corporate global funder of HIV/AIDS programs, and second overall behind the Bill & Melinda Gates Foundation.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000
Gilead Sciences, Inc.
Sung Lee, 650-524-7792
Brent Tippen, 650-653-9354
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Zonoville Investments Limited Announces Agreement on Acquisition of RUSAL Shares19.2.2018 18:19 | Pressemelding
Zonoville Investments Limited, a consortium of investors led by Renova Group and Access Industries, announced today that it had reached an agreement with Onexim Group to purchase its 6% stake in the United Company RUSAL Plc. Following completion of the purchase, Zonoville Investments Limited and its associate SUAL Partners Limited will hold, in aggregate, approximately a 26.5% interest in United Company RUSAL Plc. About Renova Renova Group of companies (www.renova.ru) is a major private Russian business group which owns and manages assets in metallurgy, mining, chemical, construction, transport, energy, telecommunications, high-tech engineering, public utilities, medicine and financial sectors in Russia and abroad (CIS, Switzerland, Italy, South Africa and the United States of America). Renova’s largest assets include its interests in UC Rusal, T Plus Group, OCTO Telematics and Swiss-based technology concerns Schmolz+Bickenbach, OC Oerlikon, and Sulzer. About Access Industries Founded
The Digital Health Technology Show: The Leading Show for Healthcare Innovation Comes to London19.2.2018 18:05 | Pressemelding
Medical innovation will take centre stage for 2018, at the largest wearables and disruptive health technology event in the world, with never before-seen devices and applications and a raft of industry-leading speakers. The Digital Health Technology Show returns to London on the 13th & 14th March 2018 at London’s Excel, gathering together more than 6,000 attendees and over 100 exhibitors. The 2018 Conference programme boasts three tracks, with over 100 hours of content programmed. Attendees can choose to attend talks on the Digital Health Disrupt Stage – covering global innovation in healthcare, the Leadership Theatre – where senior healthcare figures in the UK will discuss and debate the challenges ahead, or the Patient Engagement Stage – delivering insights into how technology is being used in the real world. There will also be demonstrations of the latest medical innovations on the Innovation Stage, which will also host a start up competition – The Health Innovation Award. Over 200 s
World Patient Safety Summit is Sold Out But Space is Available at the Breakout Sessions, Held the Day after the World Summit, at the Royal Society in London19.2.2018 13:00 | Pressemelding
The latest advances in vaccine safety, reducing unnecessary C-sections and person & patient engagement will be among the varied breakout sessions offered the day after the 6th Annual World Patient Safety, Science & Technology Summit in London by the Patient Safety Movement Foundation. The breakout sessions will convene on Sunday, February 25, 2018 at the prestigious Royal Society, the independent scientific academy of the United Kingdom and the Commonwealth, dedicated to promoting excellence in science. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180219005119/en/ Limited Space available to participate with experts at the 6th Annual World Patient Safety, Science & Technology Summit Break Out Sessions at the Royal Society in London (Photo: Business Wire) The breakout sessions are full-day working meetings structured for shared learning on existing Actionable Patient Safety Solutions (APSS) – collaborative, evidence-based pro
Tampere Attracts AV Productions with a New Incentive19.2.2018 12:41 | Pressemelding
One of the City of Tampere’s strategic goals is to be an international meeting place for creativity and innovation. The development of the experience economy is an essential focus of the city’s business policy. The incentive system is being used to attract more local, national and international productions to the Tampere region. The goal is to promote the development of the industry and to increase the number of jobs and the turnover of commercial productions in Tampere. Through the incentive system, an audiovisual production may recover some of the costs it has spent on wages and service purchases in the Tampere region. A production meeting the incentive criteria may be refunded 10–15 per cent of the accepted costs accrued in the region. Professional productions that utilise the Tampere region as their location or use expertise from the area may apply for the incentive. Thanks to the growing number of productions, Tampere will become more visible in films and TV shows, which will add
Tempo Grows Revenue by 38% in 2017 to $17.9 Million19.2.2018 11:14 | Pressemelding
Tempo, creator of efficiency-enhancing project management software solutions for Atlassian’s Jira platform, announced strong results for its 2017 fiscal year ending December 31, 2017. “2017 marks another productive and successful year for Tempo, with December our highest grossing month ever and sales across our product range exceeding expectations,” commented Agust Einarsson, CEO, “The completion of our new cloud infrastructure and successful migration of our entire customer base to Amazon Web Services (AWS) marks a strategic milestone, empowering Tempo with a more scalable underlying platform and enabling us to deploy products to customers faster.” Highlights for 2017 include: Revenue grew 38% year-over-year to US$17.9 million Almost 2,000 new customers were acquired Launched our new cloud infrastructure Expanded product footprint beyond the Atlassian environment with Tempo for Slack North American operations continued to grow More than 120 partners worldwide Celebrated our 10-year an
Morrow Sodali Announces Appointment of David Shammai as Corporate Governance Director - Cross Border19.2.2018 10:05 | Pressemelding
Morrow Sodali today announced that David Shammai has joined the firm as Corporate Governance Director - Cross Border. David joins from APG Asset Management, the Dutch pension fund manager, where in his role as senior corporate governance specialist he was involved in voting, policy, and engagement. Based in the London office, David will focus on the firm’s growing corporate governance activities across its European offices. Together with Morrow Sodali’s expanding team of corporate governance professionals, David will work to further develop the firm’s governance services – ranging from benchmarking and assessments of governance practice to board advisory on engagement with investors. “At Morrow Sodali we recognise that today many of our clients face growing needs for an in-depth and meaningful dialogue with their investors on a broadening range of topics. Having David onboard - from one of the world’s largest fiduciary asset managers - demonstrates our reinforced commitment to helping